科研之友
微信
新浪微博
Facebook
分享链接
摘要
P>Objectives Visfatin is a new cytokine that act as an insulin analogue on the insulin receptor and may link obesity and insulin resistance. It was recently shown that visfatin plays a role in plaque destabilization. However, the role of visfatin in atherosclerosis remains to be elucidated. We sought to assess whether plasma visfatin level is independently associated with inflammation, atherosclerosis and acute coronary syndromes (ACS). Design and patients Two hundred and fifty-three patients undergoing coronary angiography were divided into three subgroups: chronic coronary artery disease (CAD) (n = 102), ACS (n = 100) and control patients (n = 51). The plasma samples were thawed and analysed for circulating visfatin, monocyte chemoattractant protein 1 (MCP-1), interleukin-6 (IL-6), high sensitivity C-reactive protein (hs-CRP). The association of visfatin with risk factors, inflammation, atherosclerosis, and ACS was determined. Results Plasma visfatin levels were significantly higher in chronic CAD and ACS compared with control patients. Multiple regression analysis demonstrated that plasma visfatin levels correlated with inflammatory factors and were associated with chronic CAD (odds ratio [OR] [95% confidence interval], for second, third and fourth quartiles were 1 center dot 74 [0 center dot 96-2 center dot 69], 1 center dot 54 [0 center dot 85-2 center dot 28] and 1 center dot 84 [0 center dot 98-2 center dot 87], respectively) and ACS (ORs for second, third and fourth quartiles were 2 center dot 56 [1 center dot 57-3 center dot 34], 4 center dot 61 [1 center dot 94-10 center dot 96] and 6 center dot 52 [2 center dot 34-18 center dot 12], respectively) following adjustment for established risk factors and other inflammatory factors. Conclusions Plasma visfatin levels are significantly associated with CAD, particularly ACS, independent of well-known CAD risk factors.
- 出版日期2009-8
- 单位中国医学科学院北京协和医院
